The coronavirus pandemic has compelled regulatory bodies, such as the FDA, to ease their regulatory norms for fetal monitors to support the uninterrupted care regime of expectant mothers. Relaxations in rules have paved the way for several key players to smoothly launch fetal monitors equipped with tele-ultrasound monitoring, noninvasive features, and portable technologies. For instance, the FDA released its updated April 2020 FDA guidance amid the pandemic, under which Philips successfully launched its fetal monitor, Avalon CL, in the US on June 12, 2020. The FDA’s enforcement policy for noninvasive fetal and maternal monitoring devices aims to increase access to devices that could reduce the need for in-clinic visits and reduce the burden on doctor’s offices and hospitals during the pandemic. 

The outbreak of COVID-19 has led to various valuable partnerships among companies, which is anticipated to fuel the market's growth. For instance, in January 2021, Israel-based Nuvo Group (offering a remote pregnancy monitoring platform) entered into a commercial agreement with Axia Women’s Health, an innovative women’s health network. Under the agreement, Axia Women’s Health will be able to prescribe INVU to expectant mothers, which is expected to reduce the risk of exposure during COVID-19. 

For More Info, Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=35700261

The fetal monitoring market is expanding with the latest innovative technologies, backed by escalating research and product launches. Fetal monitoring technologies are now being streamlined to provide greater assistance in utero fetal surgeries, consisting of challenging physical fetal access and technological complications. Fetal cardiac assessments have also witnessed progress that supports high-fidelity hemodynamic and continuous physiologic monitoring, thus enabling early diagnosis and treatment. 

Research and technological advancements in fetal monitoring systems have increased focus on noninvasive monitoring procedures. Obstetrics has been introduced with noninvasive diagnosis technologies such as Doppler studies, cell-free fetal DNA assessment, electronic fetal monitoring (EFM), and fetal acid-base status.

Fetal and neonatal assessments are carried out during antepartum via percutaneous umbilical cord blood sampling and during intrapartum with fetal scalp blood sampling immediately after birth. Fetal phonocardiography has been integrated with advanced data acquisition systems and databases. Progressing data analytics, synthetic data generation by advanced mathematical models, and classifications & processing algorithms are under active research & development to increase fetal motoring data processing efficacy. 

Frequently Asked Questions (FAQ):- 

1. What are the growth opportunities in the fetal monitoring market across major regions in the future? 

The development of noninvasive, portable, and advanced fetal monitors and emerging markets and strengthening infrastructure are anticipated to offer growth opportunities in the market during the forecast period. 

2. Which device is expected to hold the largest share in the fetal monitoring market?

The devices used for fetal monitoring include, ultrasound devices, electronic maternal/fetal monitors, fetal electrodes, fetal doppler devices, uterine contraction monitors, telemetry devices, accessories & consumables, and other products. Ultrasound devices are used widely across the globe and its significant share can be attributed to technological advancements, increasing congenital anomalies, maternal mortality, and rising regulatory approvals. 

3. Which region has a well-developed fetal monitoring market? 

Among the regions North America commanded the largest share of the market. The large share of this market segment can be attributed to the presence of an established reimbufrsement structure coupled with availability of experts in the North American countries.